http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2657835-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0289b5c7b14585b669edc2580623cb4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82B1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82B1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 |
| filingDate | 2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bee503fd54e9d9cfcf7ccb2183740cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58403e5c75220f2cbd0b4db964605664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f6131b9f633289b273870ae17a358ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4322054e6e5ec0f223f01e0ffda7cb7 |
| publicationDate | 2018-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2657835-C1 |
| titleOfInvention | Method for producing a system for delivering an anticancer agent to tumor cells |
| abstract | FIELD: pharmaceuticals. n SUBSTANCE: invention relates to chemical-pharmaceutical industry and is a method for producing a system for delivering an anticancer agent to tumor cells, comprising mixing, in the presence of water, polymer-modified magnetite nanoparticles epitaxially grown on gold nanoparticles, with an organic compound chemically binding to nanoparticles and ensuring the selective penetration of nanoparticles into tumor cells, and an aqueous solution of the anticancer agent, followed by separation of the obtained nanoparticles modified by centrifugation, characterized in that polymer-modified nanoparticles are nanoparticles, obtained by heating to 120 °C in an inert gas atmosphere while stirring a mixture of diphenyl ether, oleic acid, oleylamine and 1,2-hexadecanediol, introducing iron pentacarbonyl into the mixture, maintaining the resultant mixture, followed by the introduction of a solution containing a mixture of aurichlorohydric acid trihydrate and oleylamine in diphenyl ether, pre-aged in an inert gas atmosphere, reheating of the mixture in an inert gas atmosphere from 120 °C to 250–260 °C, maintaining the mixture at 250–260 °C for 25–30 minutes and cooling to room temperature, carried out an inert gas atmosphere, maintaining the mixture at room temperature in the presence of air, adding a monohydric alcohol to the mixture and separating the magnetite nanoparticles by centrifugation, followed by treatment with a solution of a polymer selected from the group consisting of a triblock copolymer consisting of a central block of polypropylene glycol with a polymerization degree of 56 and two polyethylene glycol end blocks with a polymerization degree of 101 each, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol) – 2000] and a triblock copolymer consisting of a central block of polypropylene glycol with a polymerization degree of 30 and two end blocks of polyethylene glycol having a polymerization degree of 78 each, in an organic solvent, then by ultrasound, followed by solvent removal, water injection, ultrasound retreatment and separation of the modified nanoparticles by centrifugation, doxorubicin is used as an anticancer agent, as an organic compound providing the selective penetration of nanoparticles into human benign hyperplastic prostate cells, low molecular weight ligand of the prostatic specific membrane antigen is used, wherein the nanoparticles are first treated with a solution of doxorubicin, then with a solution of a low molecular weight ligand of the prostatic specific membrane antigen. n EFFECT: invention provides increased cytotoxicity of the system for delivering an anticancer agent to human adenocarcinoma cells. n 1 cl, 3 ex |
| priorityDate | 2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.